/TH.TO

TH.TO Stock - Theratechnologies Inc.

Q: What is the analyst price target for TH.TO?

Analyst price target information is not currently available for TH.TO.

Q: What is TH.TO's market cap?

Market capitalization information is not currently available for TH.TO.

Healthcare|Drug Manufacturers - Specialty & Generic|TSX

$4.47-4.89%

$0.23 (-4.89%) • Sep 26

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $4.92

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TH.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.81

52W High$4.73

52W Low$1.59

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$85.87M	$81.76M	$80.06M	$69.82M	$66.05M
Gross Profit	$65.42M	$62.13M	$53.78M	$46.56M	$39.15M
Gross Margin	76.2%	76.0%	67.2%	66.7%	59.3%
Operating Income	$8.17M	$-10,627,000	$-39,908,000	$-25,236,000	$-17,957,000
Net Income	$-8,306,000	$-23,957,000	$-47,237,000	$-31,725,000	$-22,667,000
Net Margin	-9.7%	-29.3%	-59.0%	-45.4%	-34.3%
EPS	$-0.17	$-0.33	$-0.50	$-0.34	$-0.29

Company Overview

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Visit Website

Earnings History & Surprises

TH.TO

Beat Rate

33%

Last 18 quarters

Avg Surprise

-52.7%

EPS vs Estimate

Beats / Misses

6/11

1 met exactly

Latest EPS

$-0.12

Q3 2025

EPS Surprise History

Q3 23

+89.7%

$-0.03vs$-0.29

Q1 24

+66.7%

$-0.08vs$-0.24

Q2 24

+16.7%

$-0.10vs$-0.12

Q3 24

+220.0%

$0.02vs$0.01

Q4 24

+100.0%

$0.06vs$0.03

Q1 25

-420.0%

$-0.16vs$0.05

Q2 25

-88.8%

$0.00vs$0.03

Q3 25

-518.0%

$-0.12vs$-0.02

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 7, 2026	—	—	—	—
Q4 2025	Oct 15, 2025	—	—	—	—
Q3 2025	Jul 9, 2025	$-0.02	$-0.12	-518.0%	✗ MISS
Q2 2025	Apr 8, 2025	$0.03	$0.00	-88.8%	✗ MISS
Q1 2025	Feb 26, 2025	$0.05	$-0.16	-420.0%	✗ MISS
Q4 2024	Oct 10, 2024	$0.03	$0.06	+100.0%	✓ BEAT
Q3 2024	Jul 10, 2024	$0.01	$0.02	+220.0%	✓ BEAT
Q2 2024	Apr 10, 2024	$-0.12	$-0.10	+16.7%	✓ BEAT
Q1 2024	Feb 21, 2024	$-0.24	$-0.08	+66.7%	✓ BEAT
Q3 2023	Sep 26, 2023	$-0.29	$-0.03	+89.7%	✓ BEAT
Q3 2023	Jul 12, 2023	$-0.06	$-0.10	-66.7%	✗ MISS
Q2 2023	Apr 12, 2023	$-0.13	$-0.15	-15.4%	✗ MISS
Q1 2023	Feb 28, 2023	$-0.07	$-0.09	-28.6%	✗ MISS
Q4 2022	Oct 13, 2022	$-0.12	$-0.08	+33.3%	✓ BEAT
Q3 2022	Jul 14, 2022	$-0.09	$-0.24	-166.7%	✗ MISS
Q2 2022	Apr 13, 2022	$-0.07	$-0.09	-28.6%	✗ MISS
Q1 2022	Feb 24, 2022	$-0.08	$-0.10	-25.0%	✗ MISS
Q4 2021	Oct 13, 2021	$-0.07	$-0.10	-42.9%	✗ MISS
Q3 2021	Jul 15, 2021	$-0.07	$-0.07	0.0%	= MET
Q2 2021	Apr 14, 2021	$-0.04	$-0.07	-75.0%	✗ MISS

Frequently Asked Questions about TH.TO

What is TH.TO's current stock price?

Theratechnologies Inc. (TH.TO) is currently trading at $4.47 per share. The stock has moved -4.89% today.

What is the analyst price target for TH.TO?

No analyst price targets are currently available for this stock.

What sector is Theratechnologies Inc. in?

Theratechnologies Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the TSX exchange.

What is TH.TO's market cap?

Theratechnologies Inc. has a market capitalization of $0.21 billion, making it a small-cap company.

Does TH.TO pay dividends?

No, Theratechnologies Inc. does not currently pay a dividend to shareholders.